Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Active not recruiting 4Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Lymphoid 2Plasma cell 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Stomach Neoplasms 1

Interventions

Fluorouracil 145Gemcitabine 141Oxaliplatin 135Capecitabine 133Leucovorin 107Irinotecan 99Bevacizumab 92Cetuximab 69Cisplatin 67pembrolizumab 61Radiotherapy 60Nivolumab 41130-nm albumin-bound paclitaxel 41Sorafenib 39Docetaxel 34Albumin-Bound Paclitaxel 31Radiosurgery 28Paclitaxel 27Surgical Procedures, Operative 25regorafenib 24Erlotinib Hydrochloride 23Panitumumab 22Cyclophosphamide 21Celecoxib 20Trastuzumab 19Radiation 18Neoadjuvant Therapy 18IFL protocol 18atezolizumab 17Carboplatin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Tiragolumab × Gastrointestinal × Clear all
NCT04933227 2024-11-14

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Hoffmann-La Roche

Phase 2 Terminated
29 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡